Forensic Analysis · Healthcare / Pharmaceuticals / Biotech · as of Aug 11, 2026

Prestige Consumer Healthcare Inc. (PBH)

A forensic read on Prestige Consumer Healthcare Inc. built from its complete SEC filings — financial-health screens, earnings quality, red flags and a price-aware rating. Reproducible math, not opinion.

C · Mixed — selective

Forensic grade

Safe

Financial health

4.5

Distress distance

Clean

Earnings quality

Forensic signals

13.7

P / E (ttm)

10.1%

ROE

$2.5B

Market cap

-4.3%

Revenue growth

This free snapshot doesn't read filing or proxy text, so the auditor-quality and governance checks that can lower a grade were not evaluated (red flags, auditor quality, say on pay, board independence). Those checks only ever lower a grade, so the full analysis can land below the grade above but never above it — treat it as the most favourable reading, not the settled one.

Prestige Consumer Healthcare Inc. earns a C (Mixed — selective) forensic quality grade, and its balance-sheet distress test reads 4.5, placing it in the Safe zone. 3 forensic signals were flagged in its latest SEC filings, led by return on invested capital.

What the filings flag

6.9%

FY2026

Return on invested capital. Return on invested capital is 6.9% in the latest fiscal year and rising from -1% — well below its ~10% cost of capital, so reinvested dollars may be destroying value, not building it.

118d

FY2025→FY2026

Inventory days. Days inventory outstanding moved from 107 to 118 FY2025→FY2026 (against cost of goods sold; inventory +8% vs -2% in cost of sales). Inventory is building a little faster than sales — watch for markdowns. There's no FY2024 figure on file for inventory, so FY2025 has no opening balance to average against — both figures are measured on period-end balances rather than the beginning-plus-ending average, since averaging only the current year would make the move track balance-sheet growth rather than the business.

$50M

FY2021–FY2023

Goodwill impairments. Took $50M of goodwill writedowns across 3 years (FY2021 ($1M), FY2022 ($340,000), FY2023 ($49M)) — about 15% of net income over the span. Writedowns mean past acquisitions underperformed what was paid for them.

Key fundamentals

Latest Revenue$1.09B

Revenue Growth YoY-4.3%

Revenue CAGR (3yr)-1.6%

Net Margin17.5%

Free Cash Flow$246.4M

Return on Equity10.1%

Debt / Equity0.53x

The forensic grade and screens above are free — no account needed. Want the AI investment read on top — the 0–100 rating, thesis, bull-vs-bear, red flags and the 12-month scenario, written from Prestige Consumer Healthcare Inc.'s actual 10-K/10-Q/8-K filings?

Generate the AI investment read →

No credit card · informational only, not investment advice · see the track record

← Browse all forensic stock analyses

Data from SEC EDGAR public filings · metrics as of Aug 11, 2026. Forensic signals flag probability, not certainty.